Xencor, Inc. (XNCR) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Xencor, Inc. (XNCR) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Seeking Alpha5/13/2026Neutral
XNCR
Xencor IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$1.22B
P/E Ratio
—
EPS
$-2.40
Beta
0.86
52W High
$18.69
52W Low
$6.92
50-Day MA
$12.76
200-Day MA
$13.26
Dividend Yield
—
Profit Margin
-177.10%
Forward P/E
68.03
PEG Ratio
0.00
About Xencor Inc
Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of cytokine and monoclonal antibody therapies designed to treat cancer patients and autoimmune diseases in the United States and internationally. The company is headquartered in Monrovia, California.
Fundamentals
| Revenue (TTM) | $97.36M |
| Gross Profit (TTM) | $-148.16M |
| EBITDA | $-201.80M |
| Operating Margin | -1724.00% |
| Return on Equity | -29.80% |
| Return on Assets | -16.20% |
| Revenue/Share (TTM) | $1.30 |
| Book Value | $8.84 |
| Price-to-Book | 2.16 |
| Price-to-Sales (TTM) | 12.53 |
| EV/Revenue | 8.65 |
| EV/EBITDA | -17.27 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -86.20% |
| Shares Outstanding | $74.14M |
| Float | $54.45M |
| % Insiders | 1.18% |
| % Institutions | 115.38% |
Historical Volatility
HV 10-Day
50.60%
HV 20-Day
52.07%
HV 30-Day
51.68%
HV 60-Day
58.63%
HV Rank
13.1%
Volatility is currently contracting
Analyst Ratings
Consensus ($28.33 target)
3
Strong Buy9
Buy2
HoldLatest News
Xencor Reports First Quarter 2026 Financial Results
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today reported financial results for the first quarter ended March 31, 2026. “Xencor continues to execute across our wholly owned clinical pipeline, with significant progress in both oncology and autoimmune disease. We look forward to presenting expansion cohort data from our Phase 1 study of XmAb819 for t.
Business Wire5/6/2026Neutral
Xencor to Host Webcast to Discuss XmAb942 and XmAb412 Data Presentations at DDW
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today reported final results from the Phase 1 study of XmAb942, a novel, potential best-in-class, long-acting anti-TL1A antibody for the treatment of inflammatory bowel disease (IBD). The results are being presented today at Digestive Disease Week® (DDW), being held in Chicago. Tomorrow, the company will a.
Business Wire5/4/2026Neutral
More HEALTHCARE Stocks
Data last updated: 7/9/2026